Immunocore (IMCR) Expected to Post Quarterly Earnings on Thursday

Key Points

• Immunocore is expected to report Q3 2026 results before markets open Thursday, November 5. Analysts forecast a loss of $0.17 per share and revenue of approximately $152.87 million; the earnings call is scheduled for November 6.
• The company missed its prior quarterly EPS estimate, reporting a $0.02 loss versus the expected $0.01 loss. Analysts project full-year EPS of $0.04 and next-year EPS of $0.22.
• IMCR shares recently traded at $32.61, while analyst sentiment remains a Moderate Buy with a consensus price target of $56.38, despite mixed recommendations ranging from Strong Buy to Sell.

Immunocore (NASDAQ:IMCR - Get Free Report) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1707) per share and revenue of $152.87 million for the quarter. Parties may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 2:00 AM ET.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. On average, analysts expect Immunocore to post $0.04 EPS for the current fiscal year and $0.22 EPS for the next fiscal year.

Immunocore Trading Up 2.0%

NASDAQ:IMCR opened at $32.61 on Thursday. Immunocore has a 12-month low of $27.50 and a 12-month high of $40.71. The firm has a market capitalization of $1.68 billion, a P/E ratio of -88.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. The business has a 50 day simple moving average of $32.59 and a 200 day simple moving average of $31.83.

Analysts Set New Price Targets

Several brokerages have weighed in on IMCR. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Immunocore in a research report on Thursday, October 15th. Zacks Research downgraded shares of Immunocore from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 3rd. Mizuho boosted their price target on shares of Immunocore from $34.00 to $35.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. TD Cowen upgraded shares of Immunocore to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Morgan Stanley set a $43.00 price objective on shares of Immunocore in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $56.38.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company's lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.